Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

The ambition is to start deliveries of Gilead Sciences’ (GILD.O), opens new tab lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund to Fight AIDS ...

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...